BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26845329)

  • 1. Structure-Guided Design of Antibodies.
    Caravella JA; Wang D; Glaser SM; Lugovskoy A
    Curr Comput Aided Drug Des; 2010; 6(2):128-38. PubMed ID: 26845329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-Guided Design of Antibodies.
    Caravella JA; Wang D; Glaser SM; Lugovskoy A
    Curr Comput Aided Drug Des; 2010 Apr; ():. PubMed ID: 20402665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computer-Aided Antibody Design: An Overview.
    Choong YS; Lee YV; Soong JX; Law CT; Lim YY
    Adv Exp Med Biol; 2017; 1053():221-243. PubMed ID: 29549642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational design of antibodies.
    Fischman S; Ofran Y
    Curr Opin Struct Biol; 2018 Aug; 51():156-162. PubMed ID: 29791878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
    Gu J; Ghayur T
    Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toward Drug-Like Multispecific Antibodies by Design.
    Sawant MS; Streu CN; Wu L; Tessier PM
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33053650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward aggregation-resistant antibodies by design.
    Lee CC; Perchiacca JM; Tessier PM
    Trends Biotechnol; 2013 Nov; 31(11):612-20. PubMed ID: 23932102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing stability of antibody via antibody engineering: stability engineering on an anti-hVEGF.
    Wang S; Liu M; Zeng D; Qiu W; Ma P; Yu Y; Chang H; Sun Z
    Proteins; 2014 Oct; 82(10):2620-30. PubMed ID: 24916692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing properties of antireceptor antibodies using kinetic computational models and experiments.
    Harms BD; Kearns JD; Su SV; Kohli N; Nielsen UB; Schoeberl B
    Methods Enzymol; 2012; 502():67-87. PubMed ID: 22208982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of Biophysical Properties and Affinity of a Human Anti-L1CAM Therapeutic Antibody through Antibody Engineering Based on Computational Methods.
    Chae H; Cho S; Jeong M; Kwon K; Choi D; Lee J; Nam W; Hong J; Lee J; Yoon S; Hong H
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational design of potent mimic peptide derived from monoclonal antibody: antibody mimic design.
    Feng J; Li Y; Zhang W; Shen B
    Immunol Lett; 2005 May; 98(2):311-6. PubMed ID: 15860233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent.
    Beiboer SH; Reurs A; Roovers RC; Arends JW; Whitelegg NR; Rees AR; Hoogenboom HR
    J Mol Biol; 2000 Feb; 296(3):833-49. PubMed ID: 10677285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toward rational antibody design: recent advancements in molecular dynamics simulations.
    Yamashita T
    Int Immunol; 2018 Apr; 30(4):133-140. PubMed ID: 29346652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of humanized antibodies: from anti-Tac to Zenapax.
    Tsurushita N; Hinton PR; Kumar S
    Methods; 2005 May; 36(1):69-83. PubMed ID: 15848076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leveraging SBDD in protein therapeutic development: antibody engineering.
    Gilliland GL; Luo J; Vafa O; Almagro JC
    Methods Mol Biol; 2012; 841():321-49. PubMed ID: 22222459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Boosting antibody developability through rational sequence optimization.
    Seeliger D; Schulz P; Litzenburger T; Spitz J; Hoerer S; Blech M; Enenkel B; Studts JM; Garidel P; Karow AR
    MAbs; 2015; 7(3):505-15. PubMed ID: 25759214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse.
    Peterson EC; Gunnell M; Che Y; Goforth RL; Carroll FI; Henry R; Liu H; Owens SM
    J Pharmacol Exp Ther; 2007 Jul; 322(1):30-9. PubMed ID: 17452421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability engineering of the human antibody repertoire.
    Rouet R; Lowe D; Christ D
    FEBS Lett; 2014 Jan; 588(2):269-77. PubMed ID: 24291820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant antibodies: alternative strategies for developing and manipulating murine-derived monoclonal antibodies.
    Peterson NC
    Lab Anim Sci; 1996 Feb; 46(1):8-14. PubMed ID: 8699826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.